{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:08:43Z","timestamp":1788570523155,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.vaccine.2012.03.047","type":"journal-article","created":{"date-parts":[[2012,3,31]],"date-time":"2012-03-31T01:05:37Z","timestamp":1333155937000},"page":"3603-3609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Assessment of inactivated human rabies vaccines: Biochemical characterization and genetic identification of virus strains"],"prefix":"10.1016","volume":"30","author":[{"given":"Stefan","family":"Finke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Karger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Freuling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2012.03.047_bib0005","first-page":"377","article-title":"Human rabies therapy: lessons learned from experimental studies in mouse models","volume":"131","author":"Jackson","year":"2008","journal-title":"Developments in Biologicals (Basel)"},{"key":"10.1016\/j.vaccine.2012.03.047_bib0010","series-title":"Virus taxonomy: classification and nomenclature of viruses: ninth report of the international committee on taxonomy of viruses","article-title":"Family Rhabdoviridae","author":"Dietzgen","year":"2011"},{"issue":"1","key":"10.1016\/j.vaccine.2012.03.047_bib0015","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3201\/eid1001.020774","article-title":"Estimating the public health impact of rabies","volume":"10","author":"Coleman","year":"2004","journal-title":"Emerging Infectious Diseases"},{"issue":"1","key":"10.1016\/j.vaccine.2012.03.047_bib0020","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3201\/eid1301.060810","article-title":"Rabies encephalitis in malaria-endemic area, Malawi, Africa","volume":"13","author":"Mallewa","year":"2007","journal-title":"Emerging Infectious Diseases"},{"issue":"32","key":"10.1016\/j.vaccine.2012.03.047_bib0025","first-page":"309","article-title":"Rabies vaccines: WHO position paper","volume":"85","author":"World Health Organisation","year":"2010","journal-title":"Weekly Epidemiological Record"},{"issue":"5","key":"10.1016\/j.vaccine.2012.03.047_bib0030","first-page":"360","article-title":"Re-evaluating the burden of rabies in Africa and Asia","volume":"83","author":"Knobel","year":"2005","journal-title":"Bulletin of the World Health Organization"},{"key":"10.1016\/j.vaccine.2012.03.047_bib0035","series-title":"Vaccines","article-title":"Rabies vaccines","author":"Plotkin","year":"2008"},{"key":"10.1016\/j.vaccine.2012.03.047_bib0040","unstructured":"World Health Organisation. Report. Discussion on WHO requirements for rabies vaccine for human use. Geneva, Switzerland, 4\u20135 May 2004; 2004."},{"key":"10.1016\/j.vaccine.2012.03.047_bib0045","first-page":"1","article-title":"Expert consultation on rabies, first report","volume":"931","author":"World Health","year":"2005","journal-title":"World Health Organization Technical Report Series"},{"issue":"8","key":"10.1016\/j.vaccine.2012.03.047_bib0050","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3201\/eid1508.081426","article-title":"Reemerging rabies and lack of systemic surveillance in People's Republic of China","volume":"15","author":"Wu","year":"2009","journal-title":"Emerging Infectious Diseases"},{"issue":"11","key":"10.1016\/j.vaccine.2012.03.047_bib0055","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1371\/journal.pntd.0000542","article-title":"Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans","volume":"3","author":"M\u00fcller","year":"2009","journal-title":"PLoS Neglected Tropical Diseases"},{"key":"10.1016\/j.vaccine.2012.03.047_bib0060","first-page":"95","article-title":"Can rabies be eradicated?","volume":"131","author":"Rupprecht","year":"2008","journal-title":"Developments in Biologicals (Basel)"},{"key":"10.1016\/j.vaccine.2012.03.047_bib0065","unstructured":"World Health Organisation. Recommendations for inactived rabies vaccine for human use produced in cell substrates and embryonated eggs. Expert Consultation on Rabies World Health Organ Tech Rep Ser. Geneva: World Health Organisation; 2007:83\u2013132."},{"key":"10.1016\/j.vaccine.2012.03.047_bib0070","unstructured":"European Medicines Agency. Guidelines on plasma-derived medicinal products. Committee for Medicinal Products for Human Use, editor. London: European Medicine Agency; 2009."},{"key":"10.1016\/j.vaccine.2012.03.047_bib0075","unstructured":"European Medicines Agency. Guidelines on the warning on transmissible agents in summary of product characteristics (SmPCs) and package leaflets for plasma-derived medicinal products. London: European Medicine Agency; 2011."},{"issue":"9764","key":"10.1016\/j.vaccine.2012.03.047_bib0080","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(10)62308-2","article-title":"Detection of prion infection in variant Creutzfeldt\u2013Jakob disease: a blood-based assay","volume":"377","author":"Edgeworth","year":"2011","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.vaccine.2012.03.047_bib0085","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s00705-010-0743-8","article-title":"Generation of recombinant European bat lyssavirus type 1 and inter-genotypic compatibility of lyssavirus genotype 1 and 5 antigenome promoters","volume":"155","author":"Orbanz","year":"2010","journal-title":"Archives of Virology"},{"issue":"6","key":"10.1016\/j.vaccine.2012.03.047_bib0090","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/elps.1150090603","article-title":"Improved staining of proteins in polyacrylamide gels including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G-250 and R-250","volume":"9","author":"Neuhoff","year":"1988","journal-title":"Electrophoresis"},{"issue":"11","key":"10.1016\/j.vaccine.2012.03.047_bib0095","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1128\/jcm.35.11.2762-2766.1997","article-title":"Heminested PCR assay for detection of six genotypes of rabies and rabies-related viruses","volume":"35","author":"Heaton","year":"1997","journal-title":"Journal of Clinical Microbiology"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2012.03.047_bib0100","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0960-9822(93)90195-T","article-title":"Rapid identification of proteins by peptide-mass fingerprinting","volume":"3","author":"Pappin","year":"1993","journal-title":"Current Biology"},{"issue":"26","key":"10.1016\/j.vaccine.2012.03.047_bib0105","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1016\/j.vaccine.2008.04.007","article-title":"Genetic characterisation of attenuated SAD rabies virus strains used for oral vaccination of wildlife","volume":"26","author":"Geue","year":"2008","journal-title":"Vaccine"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2012.03.047_bib0110","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1016\/S0264-410X(03)00422-5","article-title":"Antigen dependent adverse reactions and seroconversion of a tick-borne encephalitis vaccine in children","volume":"21","author":"Eder","year":"2003","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2012.03.047_bib0115","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00508-005-0405-0","article-title":"Hilfs- und Zusatzstoffe von Impfstoffen \u2013 Medizinische Relevanz","volume":"117","author":"Wiedermann-Schmidt","year":"2005","journal-title":"Wiener Klinische Wochenschrift"},{"key":"10.1016\/j.vaccine.2012.03.047_bib0120","series-title":"Cellular and molecular immunology","article-title":"Disease caused by immune response: hypersensitivity and autoimmunity","author":"Abbas","year":"2000"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2012.03.047_bib0125","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1016\/S0264-410X(03)00421-3","article-title":"Safety, immunogenicity and tolerability of a new pediatric tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer","volume":"21","author":"Zent","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.03.047_bib0130","unstructured":"World Health Organisation. Guidelines on transmissible spongiform encephalopathies in relation to biological and pharmaceutical products. Geneva; 2003."},{"issue":"4","key":"10.1016\/j.vaccine.2012.03.047_bib0135","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.tmaid.2010.08.001","article-title":"Tick-borne encephalitis (TBE) trends in epidemiology and current and future management","volume":"8","author":"Petri","year":"2010","journal-title":"Travel Medicine and Infectious Disease"},{"issue":"2","key":"10.1016\/j.vaccine.2012.03.047_bib0140","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.tmaid.2011.01.003","article-title":"Re: Tick-borne encephalitis (TBE) trends in epidemiology and current and future management. Comment on: Travel Med Infect Dis. 2010; 8(July (4)):233\u2013245","volume":"9","author":"Ehrlich","year":"2011","journal-title":"Travel Medicine and Infectious Disease"},{"key":"10.1016\/j.vaccine.2012.03.047_bib0145","unstructured":"World Health Organisation. Requirements for the use of animal cells as in vitro substrates for the production of biologicals. Expert Consultation on Rabies World Health Organ Tech Rep Ser. Geneva: World Health Organisation; 1998:19\u201356."},{"issue":"August (1)","key":"10.1016\/j.vaccine.2012.03.047_bib0150","first-page":"27","article-title":"Large variations in the ovalbumin content in six European influenza vaccines","volume":"2006","author":"Mark","year":"2006","journal-title":"Pharmaceutical Sciences Notes"},{"issue":"Suppl. 37","key":"10.1016\/j.vaccine.2012.03.047_bib0155","first-page":"139","article-title":"Stimulation of the immune system by different TBE-virus vaccines","volume":"293","author":"Marth","year":"2004","journal-title":"International Journal of Medical Microbiology"},{"issue":"1","key":"10.1016\/j.vaccine.2012.03.047_bib0160","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0264-410X(86)90096-4","article-title":"Immune complex-like disease in 23 persons following a booster dose of rabies human diploid cell vaccine","volume":"4","author":"Dreesen","year":"1986","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2012.03.047_bib0165","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0091-6749(87)80278-6","article-title":"The role of specific IgE and beta-propiolactone in reactions resulting from booster doses of human diploid cell rabies vaccine","volume":"80","author":"Anderson","year":"1987","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"10.1016\/j.vaccine.2012.03.047_bib0170","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/infdis\/155.5.909","article-title":"IgE and IgG antibodies to beta-propiolactone and human serum albumin associated with urticarial reactions to rabies vaccine","volume":"155","author":"Swanson","year":"1987","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.vaccine.2012.03.047_bib0175","series-title":"European pharmacopoeia","author":"Council of Europe","year":"1997"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2012.03.047_bib0180","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0264-410X(01)00329-2","article-title":"Albumin is a necessary stabilizer of TBE-vaccine to avoid fever in children after vaccination","volume":"20","author":"Marth","year":"2001","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2012.03.047_bib0185","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/0264-410X(89)90159-X","article-title":"Human diploid cell rabies vaccine purified by zonal centrifugation: a controlled study of antibody response and side effects following primary and booster pre-exposure immunizations","volume":"7","author":"Fishbein","year":"1989","journal-title":"Vaccine"},{"issue":"14","key":"10.1016\/j.vaccine.2012.03.047_bib0190","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S0264-410X(96)00049-7","article-title":"Safety and immunogenicity of Lyssavac Berna human diploid cell rabies vaccine in healthy adults","volume":"14","author":"Briggs","year":"1996","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2012.03.047_bib0195","first-page":"195","article-title":"Analysis of full-length gene sequence of a rabies vaccine strain CTN-1 for human use in China","volume":"26","author":"Shi","year":"2010","journal-title":"Chinese Journal of Virology"},{"key":"10.1016\/j.vaccine.2012.03.047_bib0200","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1073\/pnas.80.1.70","article-title":"Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus","volume":"80","author":"Dietzschold","year":"1983","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.vaccine.2012.03.047_bib0205","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.virusres.2005.03.009","article-title":"Efficacy of rabies biologics against new lyssaviruses from Eurasia","volume":"111","author":"Hanlon","year":"2005","journal-title":"Virus Research"},{"issue":"39","key":"10.1016\/j.vaccine.2012.03.047_bib0210","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1016\/j.vaccine.2009.06.095","article-title":"Antibodies induced by vaccination with purified chick embryo cell culture vaccine (PCECV) cross-neutralize non-classical bat lyssavirus strains","volume":"27","author":"Malerczyk","year":"2009","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12004392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12004392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:18:42Z","timestamp":1759400322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12004392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":42,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0264410X12004392"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.03.047","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of inactivated human rabies vaccines: Biochemical characterization and genetic identification of virus strains","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.03.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}